Trial Profile
The Efficacy and Safety of Ferriprox for the Treatment of Transfusional Iron Overload in Patients With Sickle Cell Disease or Other Anaemias
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 15 Dec 2023
Price :
$35
*
At a glance
- Drugs Deferiprone (Primary) ; Deferoxamine
- Indications Iron overload
- Focus Therapeutic Use
- Acronyms FIRST
- Sponsors ApoPharma
- 14 Dec 2023 Results of Pediatric subgroup and post hoc analysis comparing efficacy and safety of deferiprone versus deferoxamine in children with SCD, published in the Pediatric Blood and Cancer
- 14 Dec 2021 Results of subgroup analysis (n=228) of the FIRST (NCT02041299) study to assess whether the efficacy and safety of deferiprone are comparable to deferiprone in children with sickle cell disease, presented at the 63rd American Society of Hematology Annual Meeting and Exposition.
- 16 Jul 2021 Status changed from recruiting to discontinued.